BioPharmSignal logoBioPharmSignal

Biotech News

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

Exelixis (EXEL)ExelixisEarnings

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 27, 2026-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets

Related news

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

EXELExelixis2026-07-22 20:30 EST

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

IDYAIDEAYA Biosciences2026-08-04 10:00 EST

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

View all latest news

Exelixis

Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is...

Recent company news

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

EXELExelixis2026-07-22 20:30 EST

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

EXELExelixis2026-05-30 14:00 EST

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

Stock data

Close
52.20 USD
Market cap
12.2B USD
Exchange
NASDAQ
Sector
Small Molecule Drugs
Location
United States